|会社名||Aceto Corp （アセト）|
|分野（sector）||Health Care ヘルスケア|
|業種||医薬品 医療関連（Health Care）|
|概要||事業概要 アセト（Aceto Corporation）は完成剤形のジェネリック医薬品、栄養補助食品、医薬活性成分、農業中間体と農産物保護製品等の特殊化学製品のマーケティング・販売を行う。同社はヒューマンヘルス、医薬品原料と機能化学品という３つの事業セグメントを運営する。ヒューマンヘルス事業には、ジェネリック医薬品と栄養補助食品を含む。機能化学品事業は特殊化学品、農業保護製品を含む。 アセトは米国の医薬品原料・化学品販売会社。プラスチック原料、プラスチック用酸化防止剤、界面活性剤、潤滑油などの工業薬品のほか、医薬品、生化学品、栄養剤、医薬品中間物、農薬、有機中間物、色素などを販売する。本社はニューヨーク州ポ―トワシントン。 Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of 'off-the-shelf' gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.|
|本社所在地||4 Tri Harbor Court Port Washington NY 11050 USA|
|代表者氏名||William C. Kennally ウィリアム・C.・ケンナリー|
|代表者役職名||President Chief Executive Officer Director 社長兼最高経営責任者（CEO）|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the fiscal year ended 30 June 2018 Aceto Corporation revenues increased 11% to $711.4M. Net loss before extraordinary items totaled $304.8M vs. income of $11.4M. Revenues reflect Human health segment increase of 19% to $374.5M Performance Chemicals segment increase of 8% to $178M United States segment increase of 11% to $535.7M Germany segment increase of 22% to $96.7M. Net loss reflects Selling.|
Adicet Bio: Searching For Upside In Cell Therapeutics (NASDAQ:ACET) 2023/02/07 19:24:45 Seeking Alpha
All eyes are on Adicet Bio as a pivotal study is launched into its cell therapeutics. Read more to see why Adicet stands out from the CAR-T crowd.
Ontario Securities Commission Lawsuit Against Former Canntrust Executives Lands On Its Face 2022/12/20 19:53:12 Benzinga
The Ontario Securities Commission asked for a leave to withdraw the charges against former CannTrust Holdings Inc. (OTCEM:CNTTQ) CEO Peter Aceto , former chairman Eric Paul and former vice-chairman Mark Litwin on December 14 th , reported Global News. The three former executives were charged with fraud and authorizing, permitting or acquiescing in the commission of an offense. Litwin and Paul were also facing insider trading charges. Litwin and Aceto were charged with making a false prospectus and false preliminary prospectus. According to Graham Lee , a former director of quality and compliance, cultivation in unlicensed spaces was discussed “very openly” at the company. The OSC’s case fell apart when Litwin’s … Full story available on Benzinga.com
Sector Declining Stock: Adicet Bio, Inc. (NASDAQ:ACET -39.54%), Unum Group (NYSE:UNM -0.75%) 2022/12/13 00:05:15 Stock Equity
Adicet Bio, Inc. (NASDAQ:ACET) with the stream of -39.54% also noticed, India Unum Group (NYSE:UNM) encountered a rapid change of -0.75% in the last hour of Tuesday’s trading session. Adicet … The post Sector Declining Stock: Adicet Bio, Inc. (NASDAQ:ACET -39.54%), Unum Group (NYSE:UNM -0.75%) appeared first on Stocks Equity .
Adicet Bio Stock Craters on Phase 1 Clinical Data 2022/12/12 19:20:01 TipRanks
Midday trading for Adicet Bio on Monday (NASDAQ:ACET) turned sharply down. The company has lost over 36.7% so far in trading, and it all seems to be thanks to the results from ongoing Phase 1 clinical studies. The studies in question focused on a drug known as ADI-001, a treatment for B-Cell Non-Hodgkin''s Lymphoma. It''s specifically for patients who either have the disease in an aggressive form that is either “relapsed or refractory.” The news proved welcome on some fronts, including “high overall response rates” and “…a manageable side effect profile”. However, the news about the majority of patients relapsing within six months of use proved a problem.
ACET stock plunges after updating Phase 1 data for blood cancer therapy (NASDAQ:ACET) 2022/12/12 16:02:22 Seeking Alpha
Adicet Bio (ACET) dropped ~38% on Monday after the company updated data from an ongoing Phase 1 trial for its experimental CAR T cell ADI-001 in blood cancer. Read full story here.
ACET stock drops ahead of updated Phase 1 data for blood cancer therapy (NASDAQ:ACET) 2022/12/09 19:47:50 Seeking Alpha
Cancer-focused biotech Adicet Bio (ACET) fell ~12% on Friday as the company prepares for an updated data readout from its Phase 1 study for CAR T cell therapy ADI-001 in relapsed…
Adicet Bio Inc. (ACET) is an excellent investment, but the stock is overvalued/undervalued right now 2022/11/15 19:40:00 US Post News
In Monday’s session, Adicet Bio Inc. (NASDAQ:ACET) marked $20.74 per share, down from $21.27 in the previous session. While Adicet Bio Inc. has underperformed by -2.49%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ACET rose by 112.72%, with highs and lows ranging from $21.87 to […]
Adicet Bio Inc. (NASDAQ:ACET) Could Really Rise To $34.00 In 12 Months, According To Analysts. 2022/10/15 15:30:00 Marketing Sentinel
In last trading session, Adicet Bio Inc. (NASDAQ:ACET) saw 0.35 million shares changing hands with its beta currently measuring 2.15. Company’s recent per share price level of $16.61 trading at -$0.19 or -1.13% at ring of the bell on the day assigns it a market valuation of $746.29M. That closing price of ACET’s stock is … Adicet Bio Inc. (NASDAQ:ACET) Could Really Rise To $34.00 In 12 Months, According To Analysts. Read More »
Adicet Bio Inc. (NASDAQ:ACET) Currently -52.3% Below Its 52-Week High, But There May Be A Surprise Downside 2022/09/24 11:30:00 Marketing Sentinel
In last trading session, Adicet Bio Inc. (NASDAQ:ACET) saw 0.72 million shares changing hands with its beta currently measuring 2.26. Company’s recent per share price level of $13.90 trading at $0.24 or 1.76% at ring of the bell on the day assigns it a market valuation of $644.26M. That closing price of ACET’s stock is … Adicet Bio Inc. (NASDAQ:ACET) Currently -52.3% Below Its 52-Week High, But There May Be A Surprise Downside Read More »
Following Its 52-Week Low, Adicet Bio Inc. (NASDAQ: ACET)’S Share Price Rose 54.15% And Its YTD Numbers Fell -22.07% 2022/06/25 15:00:00 Marketing Sentinel
During the last session, Adicet Bio Inc. (NASDAQ:ACET)’s traded shares were 0.79 million, with the beta value of the company hitting 2.42. At the end of the trading day, the stock’s price was $13.63, reflecting an intraday gain of 13.39% or $1.61. The 52-week high for the ACET share is $21.17, that puts it down … Following Its 52-Week Low, Adicet Bio Inc. (NASDAQ: ACET)’S Share Price Rose 54.15% And Its YTD Numbers Fell -22.07% Read More »
Future Outlook And Stock Price Performance For Adicet Bio Inc. (NASDAQ: ACET) 2022/06/01 11:00:00 Marketing Sentinel
In the last trading session, 1.1 million shares of the Adicet Bio Inc. (NASDAQ:ACET) were traded, and its beta was 2.65. Most recently the company’s share price was $11.82, and it changed around $0.07 or 0.60% from the last close, which brings the market valuation of the company to $412.87M. ACET currently trades at a … Future Outlook And Stock Price Performance For Adicet Bio Inc. (NASDAQ: ACET) Read More »
FMC Files Patent Lawsuit Against Aceto US 2022/05/04 20:32:44 Wallstreet:Online
(PLX AI) – FMC Corporation files patent infringement lawsuit in the U.S. against Aceto US, LLC.The complaint, filed in the United States District Court for the District of Delaware, alleges Aceto is infringing on FMC patents relating to …
Erythromycin Market Rising Trends, Latest Technologies Research and Future Scope 2021-2028 | Ani Pharmaceuticals, Akorn, Inc., Aceto Corporation, Genesis Pharmaceuticals 2021/10/22 07:04:23 OpenPR
Erythromycin Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation, and regional growth in excessive detail. As a part of competitive analysis, the analysis study includes thorough company identification of leading players of the
Aceto Expands GMP Product Lines for Biopharmaceutical and Vaccine Manufacturing with Acquisition of A&C Bio Buffer 2021/10/12 11:30:00 Business Wire
PORT WASHINGTON, N.Y.--(BUSINESS WIRE)-- #ACBioBuffer--A&C Bio Buffers custom buffer and chemical blend portfolio complements Acetos manufacturing footprint and strengthens its presence in Europe.
Pharmaceutical Intermediates Market 2021 Competitive Analysis- Aceto Corporation, BASF SE, Chiracon GmbH, Dishman Group 2021/07/20 13:17:35 OpenPR
The report presents an in-depth assessment of the Pharmaceutical Intermediates Market including enabling technologies, key trends, market drivers, challenges, regulatory landscape, deployment models, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents forecasts for Pharmaceutical
関連キーワード （医薬品 米国株 アセト ACET Aceto Corporation）